Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587690 | 0.92 | HINT1 (0.57) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL12015139 | 0.92 | HINT1 (0.57) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL14946245 | 0.91 | HINT1 (0.54) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL25605698 | 0.91 | HPGD (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL14929063 | 0.91 | HINT1 (0.54) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL13899230 | 0.88 | HINT1 (0.57) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL14003429 | 0.88 | HINT1 (0.57) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL26808492 | 0.88 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL25807955 | 0.88 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL16471919 | 0.88 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SNRPA, SNRPA1, NSUN2 | HINT1 517/4885HPGD 4375/4885NT5E 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.